ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

alirocumab

Also written as “Alirocumab”, “alirocumab SAR236553 (REGN727)” and “Alirocumab SAR236553 (REGN727)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Coronary Artery Disease · Homozygous Familial Hypercholesterolemia · Atherosclerosis, led by 3 companies.

Drug pageAlirocumab: every studyAll 78 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 24, 201548 company-led studies, 1 open or runningNext primary completion: Dec 29, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi300 open or runningphase 4since Dec 24, 2015Feb 1, 2011none ahead
Regeneron Pharmaceuticalsits history only161 open or runningphase 4since Oct 28, 2016Nov 20, 2009Dec 29, 2026phase 2 · NCT07477704
Kobe Universityits history only20 open or runningphase 4since May 7, 2018May 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Feb 1, 2011.

  1. Jan 30, 2013Phase 1 study in HypercholesterolemiaNCT01785329 · 60 enrolled · United Kingdom
  2. Mar 14, 2013Phase 2 study in HypercholesterolemiaNCT01812707 · 100 enrolled · Japan
  3. Sep 16, 2013Phase 3 study in HypercholesterolemiaNCT01954394 · 986 enrolled · United States, Argentina, Austria and more
  4. Oct 7, 2013Phase 1 study in HypercholesterolemiaNCT01959971 · 20 enrolled · United States
  5. Dec 6, 2013Phase 3 study in HypercholesterolemiaNCT02023879 · 233 enrolled · United States, Australia, Belgium and more
  6. Apr 4, 2014Phase 3 study in HypercholesterolemiaNCT02107898 · 216 enrolled · Japan
  7. Jun 16, 2015Phase 3 study in HypercholesterolemiaNCT02476006 · 998 enrolled · Austria, Belgium, Canada and more
  8. Oct 21, 20152 phase 3 studies in HypercholesterolemiaNCT02584504, NCT02585778
  9. Dec 24, 2015Phase 4 study in DyslipidemiasNCT02642159 · 413 enrolled · United States, Australia, Brazil and more
  10. Mar 16, 2016Phase 3 study in HypercholesterolemiaNCT02715726 · 615 enrolled · China, India, Thailand
  11. Aug 31, 2016Phase 2 study in HypercholesterolemiaNCT02890992 · 42 enrolled · United States, Canada, Czechia and more
  12. Nov 29, 2016Phase 1 study in HypercholesterolemiaNCT02979015 · 35 enrolled · China
  13. Dec 5, 2016Phase 4 study in HypercholesterolemiaNCT02984982 · 206 enrolled · Japan
  14. Apr 18, 20182 phase 3 studies in HypercholesterolemiaNCT03510884, NCT03510715

TargetBeta

PCSK9 →read by rule
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia”NCIt, by rule
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SYH2053ruleCSPC Pharmaceutical Groupphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 30 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03510884Hypercholesterolemia · United States, Argentina, Austria and more3CompletedJan 14, 2021153
NCT03510715Hypercholesterolemia · Brazil, Canada, Denmark and more3CompletedFeb 17, 202018
NCT02984982Hypercholesterolemia · Japan4CompletedJul 27, 2018206
NCT02979015Hypercholesterolemia · China1CompletedNov 27, 201735
NCT02890992Hypercholesterolemia · United States, Canada, Czechia and more2CompletedSep 13, 201842
NCT02715726Hypercholesterolemia · China, India, Thailand3CompletedAug 6, 2018615
NCT02642159Dyslipidemias · United States, Australia, Brazil and more4CompletedMar 22, 2017413
NCT02585778Hypercholesterolemia · United States, Austria, Belgium and more3CompletedApr 3, 2017517
NCT02584504Hypercholesterolemia · Japan3CompletedApr 5, 2017163
NCT02476006Hypercholesterolemia · Austria, Belgium, Canada and more3CompletedApr 12, 2019998
NCT02107898Hypercholesterolemia · Japan3CompletedJan 2015216
NCT02023879Hypercholesterolemia · United States, Australia, Belgium and more3CompletedOct 27, 2014233
NCT01959971Hypercholesterolemia · United States1CompletedMay 201520
NCT01954394Hypercholesterolemia · United States, Argentina, Austria and more3CompletedJun 30, 2017986
NCT01812707Hypercholesterolemia · Japan2CompletedJan 2014100
NCT01785329Hypercholesterolemia · United Kingdom1CompletedJul 201360
NCT01670734Hypercholesterolemia · France, Moldova, Republic of1CompletedMay 201325
NCT01663402Atherosclerosis · United States, Argentina, Australia and more3CompletedJan 23, 201818,924
NCT01644474Hypercholesterolemia · United States, Belgium, Finland and more3CompletedJul 2013103
NCT01644188Hypercholesterolemia · United States, Canada, Denmark and more3CompletedMay 2014720
NCT01644175Hypercholesterolemia · United States3CompletedApr 2014316
NCT01623115Hypercholesterolemia · United States, Austria, Canada and more3CompletedApr 2014486
NCT01617655Hypercholesterolemia · United States, Canada, Netherlands and more3CompletedMay 2014107
NCT01507831Hypercholesterolemia · United States, Argentina, Belgium and more3CompletedNov 20142,341
NCT01448304Hypercholesterolemia · United States1CompletedSep 201124
NCT01448239Hypercholesterolemia · United States1CompletedMay 201124
NCT01448317Hypercholesterolemia · Japan1CompletedJan 201232
NCT01443650Hypercholesterolemia · United States1CompletedNov 201136
NCT01288469Hypercholesterolemia · United States2CompletedSep 201192
NCT01288443Hypercholesterolemia · United States2CompletedDec 2011183

How it is read

Names in the registry

  • “Alirocumab”, 28 entries
  • “alirocumab SAR236553 (REGN727)”, 8 entries
  • “Alirocumab SAR236553 (REGN727)”, 2 entries
  • “alirocumab”, 2 entries
  • “REGN727”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.